A polydopamine nanomedicine used in photothermal therapy for liver cancer knocks down the anti-cancer target NEDD8-E3 ligase ROC1 (RBX1)
Abstract Knocking down the oncogene ROC1 with siRNA inhibits the proliferation of cancer cells by suppressing the Neddylation pathway. However, methods for delivering siRNA in vivo to induce this high anticancer activity with low potential side effects are urgently needed. Herein, a folic acid (FA)-...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-10-01
|
Series: | Journal of Nanobiotechnology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12951-021-01063-4 |
_version_ | 1828137163533844480 |
---|---|
author | Zhanxia Zhang Junqian Zhang Jianhui Tian Hegen Li |
author_facet | Zhanxia Zhang Junqian Zhang Jianhui Tian Hegen Li |
author_sort | Zhanxia Zhang |
collection | DOAJ |
description | Abstract Knocking down the oncogene ROC1 with siRNA inhibits the proliferation of cancer cells by suppressing the Neddylation pathway. However, methods for delivering siRNA in vivo to induce this high anticancer activity with low potential side effects are urgently needed. Herein, a folic acid (FA)-modified polydopamine (PDA) nanomedicine used in photothermal therapy was designed for siRNA delivery. The designed nanovector can undergo photothermal conversion with good biocompatibility. Importantly, this genetic nanomedicine was selectively delivered to liver cancer cells by FA through receptor-mediated endocytosis. Subsequently, the siRNA cargo was released from the PDA nanomedicine into the tumor microenvironment by controlled release triggered by pH. More importantly, the genetic nanomedicine not only inhibited liver cancer cell proliferation but also promoted liver cell apoptosis by slowing ROC1 activity, suppressing the Neddylation pathway, enabling the accumulation of apototic factor ATF4 and DNA damage factor P-H2AX. Combined with photothermal therapy, this genetic nanomedicine showed superior inhibition of the growth of liver cancer in vitro and in vivo. Taken together, the results indicate that this biodegradable nanomedicine exhibits good target recognition, an effective pH response, application potential for genetic therapy, photothermal imaging and treatment of liver cancer. Therefore, this work contributes to the design of a multifunctional nanoplatform that combines genetic therapy and photothermal therapy for the treatment of liver cancer. |
first_indexed | 2024-04-11T18:14:23Z |
format | Article |
id | doaj.art-79e4a881a55a4fbd8712ee03ccd0dc7d |
institution | Directory Open Access Journal |
issn | 1477-3155 |
language | English |
last_indexed | 2024-04-11T18:14:23Z |
publishDate | 2021-10-01 |
publisher | BMC |
record_format | Article |
series | Journal of Nanobiotechnology |
spelling | doaj.art-79e4a881a55a4fbd8712ee03ccd0dc7d2022-12-22T04:09:58ZengBMCJournal of Nanobiotechnology1477-31552021-10-0119111510.1186/s12951-021-01063-4A polydopamine nanomedicine used in photothermal therapy for liver cancer knocks down the anti-cancer target NEDD8-E3 ligase ROC1 (RBX1)Zhanxia Zhang0Junqian Zhang1Jianhui Tian2Hegen Li3Cancer Institute, Longhua Hospital, Shanghai University of Traditional Chinese MedicineCancer Institute, Longhua Hospital, Shanghai University of Traditional Chinese MedicineCancer Institute, Longhua Hospital, Shanghai University of Traditional Chinese MedicineDepartment of Medical Oncology, Longhua Hospital, Shanghai University of Traditional Chinese MedicineAbstract Knocking down the oncogene ROC1 with siRNA inhibits the proliferation of cancer cells by suppressing the Neddylation pathway. However, methods for delivering siRNA in vivo to induce this high anticancer activity with low potential side effects are urgently needed. Herein, a folic acid (FA)-modified polydopamine (PDA) nanomedicine used in photothermal therapy was designed for siRNA delivery. The designed nanovector can undergo photothermal conversion with good biocompatibility. Importantly, this genetic nanomedicine was selectively delivered to liver cancer cells by FA through receptor-mediated endocytosis. Subsequently, the siRNA cargo was released from the PDA nanomedicine into the tumor microenvironment by controlled release triggered by pH. More importantly, the genetic nanomedicine not only inhibited liver cancer cell proliferation but also promoted liver cell apoptosis by slowing ROC1 activity, suppressing the Neddylation pathway, enabling the accumulation of apototic factor ATF4 and DNA damage factor P-H2AX. Combined with photothermal therapy, this genetic nanomedicine showed superior inhibition of the growth of liver cancer in vitro and in vivo. Taken together, the results indicate that this biodegradable nanomedicine exhibits good target recognition, an effective pH response, application potential for genetic therapy, photothermal imaging and treatment of liver cancer. Therefore, this work contributes to the design of a multifunctional nanoplatform that combines genetic therapy and photothermal therapy for the treatment of liver cancer.https://doi.org/10.1186/s12951-021-01063-4ROC1NeddylationsiRNA-loaded nanomedicinePhotothermal therapyTargeted delivery |
spellingShingle | Zhanxia Zhang Junqian Zhang Jianhui Tian Hegen Li A polydopamine nanomedicine used in photothermal therapy for liver cancer knocks down the anti-cancer target NEDD8-E3 ligase ROC1 (RBX1) Journal of Nanobiotechnology ROC1 Neddylation siRNA-loaded nanomedicine Photothermal therapy Targeted delivery |
title | A polydopamine nanomedicine used in photothermal therapy for liver cancer knocks down the anti-cancer target NEDD8-E3 ligase ROC1 (RBX1) |
title_full | A polydopamine nanomedicine used in photothermal therapy for liver cancer knocks down the anti-cancer target NEDD8-E3 ligase ROC1 (RBX1) |
title_fullStr | A polydopamine nanomedicine used in photothermal therapy for liver cancer knocks down the anti-cancer target NEDD8-E3 ligase ROC1 (RBX1) |
title_full_unstemmed | A polydopamine nanomedicine used in photothermal therapy for liver cancer knocks down the anti-cancer target NEDD8-E3 ligase ROC1 (RBX1) |
title_short | A polydopamine nanomedicine used in photothermal therapy for liver cancer knocks down the anti-cancer target NEDD8-E3 ligase ROC1 (RBX1) |
title_sort | polydopamine nanomedicine used in photothermal therapy for liver cancer knocks down the anti cancer target nedd8 e3 ligase roc1 rbx1 |
topic | ROC1 Neddylation siRNA-loaded nanomedicine Photothermal therapy Targeted delivery |
url | https://doi.org/10.1186/s12951-021-01063-4 |
work_keys_str_mv | AT zhanxiazhang apolydopaminenanomedicineusedinphotothermaltherapyforlivercancerknocksdowntheanticancertargetnedd8e3ligaseroc1rbx1 AT junqianzhang apolydopaminenanomedicineusedinphotothermaltherapyforlivercancerknocksdowntheanticancertargetnedd8e3ligaseroc1rbx1 AT jianhuitian apolydopaminenanomedicineusedinphotothermaltherapyforlivercancerknocksdowntheanticancertargetnedd8e3ligaseroc1rbx1 AT hegenli apolydopaminenanomedicineusedinphotothermaltherapyforlivercancerknocksdowntheanticancertargetnedd8e3ligaseroc1rbx1 AT zhanxiazhang polydopaminenanomedicineusedinphotothermaltherapyforlivercancerknocksdowntheanticancertargetnedd8e3ligaseroc1rbx1 AT junqianzhang polydopaminenanomedicineusedinphotothermaltherapyforlivercancerknocksdowntheanticancertargetnedd8e3ligaseroc1rbx1 AT jianhuitian polydopaminenanomedicineusedinphotothermaltherapyforlivercancerknocksdowntheanticancertargetnedd8e3ligaseroc1rbx1 AT hegenli polydopaminenanomedicineusedinphotothermaltherapyforlivercancerknocksdowntheanticancertargetnedd8e3ligaseroc1rbx1 |